Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. March is WOMEN’S HISTORY MONTH and BioBuzz will celebrate by featuring Women in the BioHealth industry all month, especially in “5 Questions With…”. This week we continue the series with Destinie Burgan, Upstream Supervisor of Manufacturing, Emergent BioSolutions.
The BioHealth Capital Region (BHCR) had a remarkable 2020, and there is palpable momentum and excitement in the air as we approach the end of Q1 2021. How will the pandemic impact the region’s push to be “Top 3 by 2023?” Where will this significant momentum lead? These questions are yet to be answered.
Emergent Biosolutions Seeks New Talent to Support Global COVID-19 Vaccination Push, Expanding Project Portfolio
Maryland’s leading vaccine manufacturer, Emergent Biosolutions (Emergent), is a critical cog in the vaccine manufacturing and distribution engine as it has multiple COVID-19 vaccine manufacturing partnerships, including partnerships with J&J and AstraZeneca, among others. Emergent also partners with the Biomedical Advanced Research and Development Authority (BARDA), which provided approximately $628.3M in funding to the company as part of Operation Warp Speed.
5 Questions with Doug White, Senior Vice President, Devices Business Unit Head, Emergent BioSolutions
Doug White joined Emergent in 2017 and serves as head of the devices business unit. He previously served as vice president and general manager of Molecular Diagnostics & Women’s Health at Becton Dickenson Diagnostics. Before joining Becton Dickenson Diagnostics, he was chief executive officer of OpGen Inc.
2020 was a year like no other for BioHealth Capital Region (BCHR) biotechs, and this year is expected to bring substantial growth across many sectors.
Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.
‘We take a lot of pride in that’: Md.-based manufacturer Emergent BioSolutions of 1-shot vaccine awaits approvalPublished on :
Across the region, the frustration is growing. People who want to be vaccinated but can’t get an appointment are speaking out. Natalie Gora is a Montgomery County resident turned away from a Prince George’s County clinic she says, “I don’t think it’s fair. ” Even as the state expands to more than 100 active vaccination…
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™ GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, [….]
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.